Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioNexus Gene LabBGLC +5.81%54 Debt-to-Equity is 0.03 as of Mar. 2026, which is 50% above its 10-year median of 0.02. GuruFocus rates BGLC with a GF Score™ of 54/100 and a GF Value™ of $2.14 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 1,421 Chemicals companies, BioNexus Gene Lab ranks better than 91.2% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for BioNexus Gene Lab's Debt-to-Equity or its related term are showing as below:
BGLC'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.02 Max: 0.08
Current: 0.03
During the past 8 years, the highest Debt-to-Equity Ratio of BioNexus Gene Lab was 0.08. The lowest was 0.00. And the median was 0.02.
BGLC's Debt-to-Equity is ranked better than 91.2% of 1421
companies
in the Chemicals industry
Industry Median: 0.36
vs BGLC: 0.03
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
BioNexus Gene Lab Debt-to-Equity Related Terms
BioNexus Gene Lab Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for BioNexus Gene Lab's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BGLC vs VYST, QGAI, CNEY: Debt-to-Equity Comparison
For the Specialty Chemicals subindustry, BioNexus Gene Lab's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioNexus Gene Lab Debt-to-Equity vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, BioNexus Gene Lab's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where BioNexus Gene Lab's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioNexus Gene Lab (BGLC) has a Debt-to-Equity of 0.03 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on BioNexus Gene Lab and its competitors. This is 50% above median its historical median of 0.02. According to the industry distribution chart, BioNexus Gene Lab ranks #125 out of 1421 companies in the Chemicals industry, placing it in the top 8.8%.
Is BioNexus Gene Lab's Debt-to-Equity too high?
BioNexus Gene Lab's current Debt-to-Equity of 0.03 is 50% above median its 10-year median of 0.02. The Chemicals industry median Debt-to-Equity is 0.36. BioNexus Gene Lab's value of 0.03 is 91.7% below this industry median. Based on the distribution chart, BioNexus Gene Lab ranks #125 out of 1421 companies in the Chemicals industry, which is in the top quartile — a strong position relative to peers. Overall, BioNexus Gene Lab has a GF Score™ of 54/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioNexus Gene Lab's Debt-to-Equity compare to VYST and QGAI?
According to the Chemicals industry distribution chart, BioNexus Gene Lab ranks #125 out of 1421 companies for Debt-to-Equity. This places BioNexus Gene Lab in the top 9% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.36. BioNexus Gene Lab's value of 0.03 is 91.7% below this benchmark. While the company's 10-year median is 0.02 vs. the industry median of 0.36, BioNexus Gene Lab has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Chemicals company?
The median Debt-to-Equity among Chemicals companies is 0.36, based on 1,421 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioNexus Gene Lab's current Debt-to-Equity of 0.03 is 91.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on BioNexus Gene Lab and its competitors. For the Chemicals industry, the median Debt-to-Equity is 0.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioNexus Gene Lab's current Debt-to-Equity is 0.03, which is 50% above median its own 10-year median of 0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioNexus Gene Lab stock overvalued right now?
Based on GuruFocus' analysis, BioNexus Gene Lab (BGLC) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.14, compared to a current price of $1.64 — trading 23.4% below its estimated fair value. The current Debt-to-Equity is 0.03, which is 50% above median its 10-year median of 0.02 and 91.7% below the Chemicals industry median of 0.36. BioNexus Gene Lab's overall GF Score™ is 54/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For BioNexus Gene Lab (BGLC), the current Debt-to-Equity is 0.03 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioNexus Gene Lab (BGLC) Overvalued in 2026?
Based on GuruFocus' analysis, BioNexus Gene Lab stock appears to be undervalued.
The current stock price of $1.64 is trading 23.4% below its estimated GF Value™ of $2.14.
GuruFocus considers BioNexus Gene Lab to be Modestly Undervalued.
Key valuation signals for BGLC:
Debt-to-Equity: 0.03 (50% above median its 10-year median of 0.02)
GF Value™: $2.14 vs. price of $1.64 (23.4% below fair value)
Industry Position: 91.7% below the Chemicals median (#125 of 1421)
No single metric tells the full story. See the BGLC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioNexus Gene Lab Corp is a Wyoming corporation with two principal operating subsidiaries in Malaysia: Chemrex Corporation Sdn. Bhd. (Chemrex) and MRNA Scientific Sdn. Bhd. (MRNA Scientific). Chemrex is engaged in the distribution of chemical raw materials, mainly for industrial applications in Southeast Asia. MRNA Scientific is engaged in the development and provision of blood-based genomic screening services intended to support early disease risk assessment and health management. Trading of industrial chemicals- Includes trading of industrial chemicals. Provision for genomic screening services- includes in commercializing proprietary blood-based diagnostic test for early disease detection. Investment holding- Investment holding, are its segments.
54GF Score
Get the complete analysis for BGLC
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BGLC has been successfully added to your 
